Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.35 |
| ▸ | OXTR | P30559 | 10/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553268 | 0.90 | AVPR2 (0.34) | GRM1AVPR2OXTRAVPR1ADGAT2 | |
| SCHEMBL25324449 | 0.90 | AVPR2 (0.34) | GRM1AVPR2OXTRAVPR1ADGAT2 | |
| SCHEMBL30553166 | 0.89 | ADRA1A (0.34) | GRM1AVPR2OXTRAVPR1A | |
| SCHEMBL25327881 | 0.89 | ADRA1A (0.34) | GRM1AVPR2OXTRAVPR1A | |
| SCHEMBL30553302 | 0.88 | GRM1 (0.36) | GRM1AVPR2DGAT2CYP1A2CYP3A4 | |
| SCHEMBL25325627 | 0.88 | GRM1 (0.36) | GRM1AVPR2DGAT2CYP1A2CYP3A4 | |
| SCHEMBL30553200 | 0.88 | ADRA1A (0.39) | GRM1DGAT2ACACB | |
| SCHEMBL25326517 | 0.88 | ADRA1A (0.39) | GRM1DGAT2ACACB | |
| SCHEMBL25324783 | 0.88 | AVPR2 (0.33) | GRM1AVPR2OXTRACACB | |
| SCHEMBL30553178 | 0.88 | AVPR2 (0.33) | GRM1AVPR2OXTRACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GRM1 775/4885AVPR2 132/4885OXTR 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.